NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Clinical trials for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) explained in plain language.
Never miss a new study
Get alerted when new NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) trials appear
Sign up with your email to follow new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New eye injection aims to stretch time between treatments for leading cause of vision loss
Disease control CompletedThis study tested whether a new type of eye injection called faricimab could help people with 'wet' age-related macular degeneration (AMD) go longer between treatments. Researchers gave 742 older adults three monthly loading injections and then monitored how many weeks passed bef…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Sponsor: Rigshospitalet, Denmark • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Doctors track Real-World results of Vision-Saving eye injections
Disease control CompletedThis study observed how well an eye injection called brolucizumab worked in everyday medical practice for patients with two common causes of vision loss: 'wet' age-related macular degeneration (AMD) and diabetic macular edema (DME). It followed 572 patients in Germany for up to t…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC